Autolus Therapeutics
AUTL
66 hedge funds and large institutions have $106M invested in Autolus Therapeutics in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 14 increasing their positions, 21 reducing their positions, and 7 closing their positions.
19,400% more call options, than puts
Call options by funds: $195K | Put options by funds: $1K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
1% less funds holding
Funds holding: 67 → 66 (-1)
1.61% less ownership
Funds ownership: 55.92% → 54.3% (-1.6%)
27% less capital invested
Capital invested by funds: $144M → $106M (-$38.2M)
33% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KHCM
Kettle Hill Capital Management
New York
|
+$266K |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$216K |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
+$164K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$76.7K |
| 5 |
LPL Financial
San Diego,
California
|
+$68.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$3M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$882K |
| 3 |
JP Morgan Chase
New York
|
-$545K |
| 4 |
Millennium Management
New York
|
-$470K |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$184K |
AUTL Hedge Fund Activity: Q3 2022 in Review
66 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q3 2022, worth a combined $106M — down 27% from $144M a quarter earlier.
Fund positioning in AUTL was balanced in Q3 2022: 7 funds opened new positions, 7 closed out, 14 added to existing stakes and 21 trimmed.
The largest buyer was Kettle Hill Capital Management, opening a new position worth an estimated $266K. The largest seller was Citadel Advisors, cutting an estimated $3M.
- 66 institutional investors held Autolus Therapeutics (AUTL) as of Q3 2022, down from 67 in Q2 2022.
- Funds reported $106M of Autolus Therapeutics stock for Q3 2022, down 27% quarter-over-quarter.
- 7 funds opened new Autolus Therapeutics positions in Q3 2022 and 7 closed out, a net change of 0 holders.
- The largest Autolus Therapeutics buyer in Q3 2022 was Kettle Hill Capital Management, an estimated $266K added.
- The largest Autolus Therapeutics seller in Q3 2022 was Citadel Advisors, an estimated $3M sold.
Based on aggregated 13F filings for Q3 2022.